Innoviva (INVA) Non Operating Investment Income (2020 - 2023)
Innoviva (INVA) posted Non Operating Investment Income of $22.7 million for Q3 2023, up 355.52% on a QoQ basis from -$8.9 million in Q3 2022, and up 355.52% year-over-year from $5.0 million in Q3 2022.
Innoviva (INVA) Non Operating Investment Income (2020 - 2023) Analysis & Trends
Innoviva's Non Operating Investment Income history runs 4 years deep, the most recent figure standing at $22.7 million for Q3 2023.
- Quarterly Non Operating Investment Income rose 355.52% year-over-year to $22.7 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was -$54.2 million (down 194.95% YoY) and the FY2024 annual result came in at -$5.3 million, down 120.83% from the prior year.
- Non Operating Investment Income was $22.7 million for Q3 2023 at Innoviva, up from -$8.9 million in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $134.0 million in Q3 2021 and bottomed at -$58.6 million in Q2 2022.
- A 4-year average of $16.5 million and a median of $21.9 million in 2020 frame the typical range for Non Operating Investment Income.
- Annual changes were most pronounced in 2021 — Non Operating Investment Income surged 556.19% — and 2022, when it slumped 229.32%.
- Innoviva's Non Operating Investment Income stood at -$38.1 million in 2020, then soared by 451.65% to $134.0 million in 2021, then tumbled by 106.63% to -$8.9 million in 2022, then soared by 355.52% to $22.7 million in 2023.
- Business Quant data shows INVA's Non Operating Investment Income at $22.7 million in Q3 2023, -$8.9 million in Q3 2022, and -$58.6 million in Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Innoviva | 1.58 Bn | 979.49 Mn | 75.83 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 22.70 Mn |
| Sep 30, 2023 | 22.70 Mn |
| Sep 30, 2022 | -8.88 Mn |
| Sep 30, 2022 | -8.88 Mn |
| Jun 30, 2022 | -58.60 Mn |
| Jun 30, 2022 | -58.60 Mn |
| Mar 31, 2022 | -9.41 Mn |
| Mar 31, 2022 | -9.41 Mn |
| Sep 30, 2021 | 133.97 Mn |
| Sep 30, 2021 | 133.97 Mn |
| Jun 30, 2021 | 45.32 Mn |
| Jun 30, 2021 | 45.32 Mn |
| Mar 31, 2021 | 55.05 Mn |
| Mar 31, 2021 | 55.05 Mn |
| Dec 31, 2020 | -38.10 Mn |
| Dec 31, 2020 | -38.10 Mn |
| Sep 30, 2020 | -29.37 Mn |
| Sep 30, 2020 | -29.37 Mn |
| Jun 30, 2020 | 46.70 Mn |
| Jun 30, 2020 | 46.70 Mn |